Other analysts have also recently issued research reports about the company. Barclays increased their target price on Shire from GBX 3,900 ($50.96) to GBX 4,700 ($61.41) and gave the stock an equal weight rating in a report on Friday, August 10th. Liberum Capital reaffirmed a hold rating on shares of Shire in a research note on Tuesday, July 10th. Berenberg Bank lowered Shire to a hold rating and upped their price target for the company from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research note on Thursday, September 6th. Shore Capital reaffirmed a hold rating on shares of Shire in a research note on Monday, July 2nd. Finally, UBS Group reaffirmed a neutral rating and set a GBX 4,500 ($58.80) price target on shares of Shire in a research note on Wednesday, August 1st. Eight analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Shire presently has a consensus rating of Buy and a consensus price target of GBX 4,693.14 ($61.32).
Shares of SHP stock traded up GBX 48 ($0.63) during trading hours on Friday, hitting GBX 4,300.50 ($56.19). 2,961,119 shares of the company’s stock were exchanged, compared to its average volume of 3,140,000. Shire has a 52 week low of GBX 2,940.50 ($38.42) and a 52 week high of GBX 5,021 ($65.61).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Recommended Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.